If You Invested in Invitro Internat (IVRO)

InVitro International (OTCQB: IVRO) is described in its public communications as a pioneer developer and marketer of globally approved NON-Animal test technologies. The company is associated with the pharmaceutical preparation manufacturing industry and focuses on in vitro safety testing methods that do not rely on animal testing. According to its press releases, InVitro International has been active for decades and emphasizes a long-term vision of helping industry move from animal-based safety testing to in vitro testing.

InVitro International highlights that its NON-Animal test technologies are used for safety testing and that its methods have received global approvals. The company states that it serves large industries, mentioning cosmetics, chemical companies, and manufacturers of various adhesives as examples of markets where its in vitro test methods are applied. These customers are described as being located globally, reflecting the company’s focus on international adoption of non-animal testing approaches.

In its public statements, the company links its business to a broader global movement toward animal welfare and regulatory acceptance of non-animal testing. InVitro International notes that regulatory agencies in multiple regions have announced plans to cease funding for animal testing and that some agencies indicate they will accept OECD-validated non-animal test results. The company positions its test methods as aligned with these regulatory directions, stating that it offers such validated non-animal test methods.

InVitro International also comments on its financial and strategic direction. The company reports a long multi-year record of profitability in its fiscal updates and describes a strategy that includes both organic growth and growth through mergers and acquisitions. Public releases mention efforts to pursue mergers with privately owned testing laboratories, including a Memorandum of Understanding (MOU) to merge with a European-based organization focused on non-animal testing that has served its market for more than two decades. The company describes this as part of a plan to participate more extensively in markets where the movement toward humane, non-animal safety testing has been strong.

InVitro International’s communications also reference work with external advisors to support its corporate growth plan. The company has announced an engagement with a consulting and investment banking firm to assist with business advising, management, and strategy related to its growth objectives. It has further indicated interest in enhancing its presence on the OTC Markets by applying to move from the OTC Pink market to OTCQB, citing potential benefits in visibility and credibility, particularly in connection with potential merger and acquisition targets.

Across its public statements, InVitro International consistently emphasizes several themes: the development and marketing of non-animal test technologies, alignment with global regulatory and legislative trends favoring in vitro testing, a mission tied to animal welfare, and a growth strategy that combines continued profitability with expansion through mergers and acquisitions. The company describes itself as operating in an environment shaped by prior economic challenges, including the effects of Covid-related conditions and inflation, and portrays its financial performance and strategic initiatives as responses to these conditions while maintaining its focus on non-animal safety testing.